• Life sciences companies are adopting AI to accelerate decisions amid rising development costs, clinical attrition and patent expirations, ISG's 2026 report finds.
• Legacy platforms, fragmented data and inconsistent semantics limit AI deployment at scale and reduce output reliability.
• Demand is strongest for AI embedded in scientific workflows with transparent evidence and expert validation.
• Buyers favor bounded AI workflows that preserve expert accountability as they move from demonstrations to measurable production results.
• Managed, transaction-based and outcome-linked sourcing arrangements are expanding across life sciences analytics and AI services.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ISG - Information Services Group Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20261022972832) on October 22, 2026, and is solely responsible for the information contained therein.